BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Charalambous S, Grant AD, Innes C, Hoffmann CJ, Dowdeswell R, Pienaar J, Fielding KL, Churchyard GJ. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS 2010;24 Suppl 5:S5-13. [PMID: 21079429 DOI: 10.1097/01.aids.0000391010.02774.6f] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Smith T, Samandari T, Abimbola T, Marston B, Sangrujee N. Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana. J Acquir Immune Defic Syndr 2015;70:e84-93. [PMID: 26258564 DOI: 10.1097/QAI.0000000000000783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
2 Edessa D, Likisa J. A Description of Mortality Associated with IPT plus ART Compared to ART Alone among HIV-Infected Individuals in Addis Ababa, Ethiopia: A Cohort Study. PLoS One 2015;10:e0137492. [PMID: 26348618 DOI: 10.1371/journal.pone.0137492] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
3 Nyathi S, Dlodlo RA, Satyanarayana S, Takarinda KC, Tweya H, Hove S, Matambo R, Mandewo W, Nyathi K, Sibanda E, Harries AD. Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe. PLoS One 2019;14:e0223076. [PMID: 31581271 DOI: 10.1371/journal.pone.0223076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
4 Yan I, Bendavid E, Korenromp EL. Antiretroviral Treatment Scale-Up and Tuberculosis Mortality in High TB/HIV Burden Countries: An Econometric Analysis. PLoS One 2016;11:e0160481. [PMID: 27536864 DOI: 10.1371/journal.pone.0160481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
5 Badje A, Moh R, Gabillard D, Guéhi C, Kabran M, Ntakpé JB, Carrou JL, Kouame GM, Ouattara E, Messou E, Anzian A, Minga A, Gnokoro J, Gouesse P, Emieme A, Toni TD, Rabe C, Sidibé B, Nzunetu G, Dohoun L, Yao A, Kamagate S, Amon S, Kouame AB, Koua A, Kouamé E, Daligou M, Hawerlander D, Ackoundzé S, Koule S, Séri J, Ani A, Dembélé F, Koné F, Oyebi M, Mbakop N, Makaila O, Babatunde C, Babatunde N, Bleoué G, Tchoutedjem M, Kouadio AC, Sena G, Yededji SY, Karcher S, Rouzioux C, Kouame A, Assi R, Bakayoko A, Domoua SK, Deschamps N, Aka K, N'Dri-Yoman T, Salamon R, Journot V, Ahibo H, Ouassa T, Menan H, Inwoley A, Danel C, Eholié SP, Anglaret X; Temprano ANRS 12136 Study Group. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health 2017;5:e1080-9. [PMID: 29025631 DOI: 10.1016/S2214-109X(17)30372-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 45] [Article Influence: 24.0] [Reference Citation Analysis]
6 Maharaj B, Gengiah TN, Yende-Zuma N, Gengiah S, Naidoo A, Naidoo K. Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART. Int J Tuberc Lung Dis 2017;21:537-43. [PMID: 28399969 DOI: 10.5588/ijtld.16.0775] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
7 Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Mosimaneotsile B, Motsamai OI, Shang N, Rose CE, Shepherd J. Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. AIDS 2015;29:351-9. [PMID: 25686683 DOI: 10.1097/QAD.0000000000000535] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
8 Charan J, Goyal JP, Reljic T, Emmanuel P, Patel A, Kumar A. Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis. Pediatr Infect Dis J 2018;37:773-80. [PMID: 29280783 DOI: 10.1097/INF.0000000000001879] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
9 Briggs MA, Emerson C, Modi S, Taylor NK, Date A. Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature. J Acquir Immune Defic Syndr 2015;68 Suppl 3:S297-305. [PMID: 25768869 DOI: 10.1097/QAI.0000000000000497] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
10 Daftary A, Hirsch-Moverman Y, Kassie GM, Melaku Z, Gadisa T, Saito S, Howard AA. A Qualitative Evaluation of the Acceptability of an Interactive Voice Response System to Enhance Adherence to Isoniazid Preventive Therapy Among People Living with HIV in Ethiopia. AIDS Behav 2017;21:3057-67. [PMID: 27221743 DOI: 10.1007/s10461-016-1432-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
11 Lawn SD, Harries AD, Meintjes G, Getahun H, Havlir DV, Wood R. Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2012;26:2121-33. [PMID: 22695302 DOI: 10.1097/QAD.0b013e3283565dd1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
12 Kipp AM, Pungrassami P, Nilmanat K, Sengupta S, Poole C, Strauss RP, Chongsuvivatwong V, Van Rie A. Socio-demographic and AIDS-related factors associated with tuberculosis stigma in southern Thailand: a quantitative, cross-sectional study of stigma among patients with TB and healthy community members. BMC Public Health 2011;11:675. [PMID: 21878102 DOI: 10.1186/1471-2458-11-675] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
13 Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, Mosimaneotsile B, Motsamai OI, Bozeman L, Davis MK, Talbot EA, Moeti TL, Moffat HJ, Kilmarx PH, Castro KG, Wells CD. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. The Lancet 2011;377:1588-98. [DOI: 10.1016/s0140-6736(11)60204-3] [Cited by in Crossref: 216] [Cited by in F6Publishing: 132] [Article Influence: 21.6] [Reference Citation Analysis]
14 Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, Sterling TR, Chaisson RE, Williams BG, Harries AD, Granich RM. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med 2012;9:e1001270. [PMID: 22911011 DOI: 10.1371/journal.pmed.1001270] [Cited by in Crossref: 221] [Cited by in F6Publishing: 207] [Article Influence: 24.6] [Reference Citation Analysis]
15 Atey TM, Bitew H, Asgedom SW, Endrias A, Berhe DF. Does Isoniazid Preventive Therapy Provide Better Treatment Outcomes in HIV-Infected Individuals in Northern Ethiopia? A Retrospective Cohort Study. AIDS Res Treat 2020;2020:7025738. [PMID: 32411454 DOI: 10.1155/2020/7025738] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Tchakounte Youngui B, Coffie P, Messou E, Poda A, Fortes Deguenonvo L, Hawerlander D, Minga A, Balestre E, Dabis F, Marcy O. Incidence of Tuberculosis During the First Year of Antiretroviral Treatment in West African HIV-Infected Adults. Open Forum Infect Dis 2020;7:ofaa203. [PMID: 32607387 DOI: 10.1093/ofid/ofaa203] [Reference Citation Analysis]
17 Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, Cohn S, Efron A, Chaisson RE, Golub JE. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis 2013;13:852-8. [PMID: 23954450 DOI: 10.1016/S1473-3099(13)70187-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
18 Padmapriyadarsini C, Sekar L, Reddy D, Chitra A, Poornagangadevi N, Selvaraj M, Bhavani PK, Mothi SN, Nandagopal K, Vennila S, Tamizhselvan M, Maheshmanisha J, Agarwal U, Rewari BB, Swaminathan S. Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting. Indian J Med Res 2020;152:648-55. [PMID: 34145105 DOI: 10.4103/ijmr.IJMR_1582_18] [Reference Citation Analysis]
19 Trinh TT, Han DT, Bloss E, Le TH, Vu TT, Mai AH, Nguyen NV, Nguyen LT, Dinh SN, Whitehead S. Implementation and evaluation of an isoniazid preventive therapy pilot program among HIV-infected patients in Vietnam, 2008-2010. Trans R Soc Trop Med Hyg 2015;109:653-9. [PMID: 26385936 DOI: 10.1093/trstmh/trv074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
20 Chehab JC, Vilakazi-Nhlapo AK, Vranken P, Peters A, Klausner JD. Current integration of tuberculosis (TB) and HIV services in South Africa, 2011. PLoS One 2013;8:e57791. [PMID: 23469242 DOI: 10.1371/journal.pone.0057791] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
21 Moolphate S, Lawpoolsri S, Pungrassami P, Sanguanwongse N, Yamada N, Kaewkungwal J. Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand. Glob J Health Sci 2013;5:60-70. [PMID: 23777722 DOI: 10.5539/gjhs.v5n4p60] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
22 Shayo GA, Chitama D, Moshiro C, Aboud S, Bakari M, Mugusi F. Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study. BMC Public Health 2017;18:35. [PMID: 28724374 DOI: 10.1186/s12889-017-4597-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
23 Hosseinipour MC, Bisson GP, Miyahara S, Sun X, Moses A, Riviere C, Kirui FK, Badal-Faesen S, Lagat D, Nyirenda M, Naidoo K, Hakim J, Mugyenyi P, Henostroza G, Leger PD, Lama JR, Mohapi L, Alave J, Mave V, Veloso VG, Pillay S, Kumarasamy N, Bao J, Hogg E, Jones L, Zolopa A, Kumwenda J, Gupta A; Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. Lancet 2016;387:1198-209. [PMID: 27025337 DOI: 10.1016/S0140-6736(16)00546-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 24] [Article Influence: 8.6] [Reference Citation Analysis]
24 Hoffmann CJ, Maritz J, van Zyl GU. CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone. Trop Med Int Health 2016;21:219-23. [PMID: 26584666 DOI: 10.1111/tmi.12639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]